摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

2-(4-乙基哌嗪-1-YL)苯甲醛 | 865203-79-8

中文名称
2-(4-乙基哌嗪-1-YL)苯甲醛
中文别名
——
英文名称
2-(4-ethylpiperazin-1-yl)benzaldehyde
英文别名
——
2-(4-乙基哌嗪-1-YL)苯甲醛化学式
CAS
865203-79-8
化学式
C13H18N2O
mdl
MFCD05864669
分子量
218.299
InChiKey
PCAHVXDDADHPLQ-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    1.7
  • 重原子数:
    16
  • 可旋转键数:
    3
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.461
  • 拓扑面积:
    23.6
  • 氢给体数:
    0
  • 氢受体数:
    3

安全信息

  • 海关编码:
    2933599090
  • 储存条件:
    室温

SDS

SDS:e12bc073df8ca247b3901c4c6964bfe4
查看

反应信息

  • 作为反应物:
    描述:
    2-(4-乙基哌嗪-1-YL)苯甲醛 在 [ruthenium(II)(η6-1-methyl-4-isopropyl-benzene)(chloride)(μ-chloride)]2D(+)-10-樟脑磺酸 作用下, 以 甲苯 为溶剂, 140.0 ℃ 、101.33 kPa 条件下, 反应 18.0h, 以49%的产率得到2-Ethyl-1,2,3,4-tetrahydropyrazino[1,2-a]indole
    参考文献:
    名称:
    钌催化“特权”哌嗪核上的β-C(sp 3)–H功能化
    摘要:
    使用钌催化已经公开了在“特权的”哌嗪核上的β-C(sp 3)-H功能化。提出了钌从邻哌嗪基(杂)芳基醛催化的各种哌嗪稠合的吲哚的催化合成。该转化通过哌嗪的脱氢,然后将瞬时烯胺部分分子内亲核加成到羰基上并进行芳构化级联而发生。
    DOI:
    10.1039/c7cc05604d
  • 作为产物:
    描述:
    N-乙基哌嗪2-氟苯甲醛potassium carbonate 作用下, 以 N,N-二甲基甲酰胺 为溶剂, 反应 4.0h, 以79%的产率得到2-(4-乙基哌嗪-1-YL)苯甲醛
    参考文献:
    名称:
    钌催化“特权”哌嗪核上的β-C(sp 3)–H功能化
    摘要:
    使用钌催化已经公开了在“特权的”哌嗪核上的β-C(sp 3)-H功能化。提出了钌从邻哌嗪基(杂)芳基醛催化的各种哌嗪稠合的吲哚的催化合成。该转化通过哌嗪的脱氢,然后将瞬时烯胺部分分子内亲核加成到羰基上并进行芳构化级联而发生。
    DOI:
    10.1039/c7cc05604d
点击查看最新优质反应信息

文献信息

  • [EN] NOVEL BENZYL(IDENE)-LACTAM DERIVATIVES<br/>[FR] NOUVEAUX DERIVES DE BENZYL(IDENE)-LACTAME
    申请人:PFIZER PROD INC
    公开号:WO2005090300A1
    公开(公告)日:2005-09-29
    The present invention relates to novel benzyl(idene)-lactam derivatives, compounds of the formula (I) wherein R1 is a group of the formula G1 or G2 depicted below, wherein R1, R3, R6, R13, X, a, n and m are as defined herein, their pharmaceutically acceptable salts, and pharmaceutical compositions which include selective antagonists, inverse agonists and partial agonists of serotonin 1 (5-HT1) receptors, specifically, of one or both of the 5-HT1A and 5-HT1B receptors. The compounds of the invention are useful in treating or preventing depression, anxiety, obsessive compulsive disorder (OCD) and other disorders for which a 5-HT1 agonist or antagonist is indicated and have reduced potential for cardiac side effects, in particular QTc prolongation.
    本发明涉及新型苄基(亚)内酰胺衍生物,化合物的结构如下式(I)所示,其中R1是下图所示的G1或G2的基团,其中R1、R3、R6、R13、X、a、n和m的定义如本文所述,其药学上可接受的盐,以及包括选择性5-羟色胺1(5-HT1)受体的拮抗剂、逆向激动剂和部分激动剂的药物组合物,具体地,是5-HT1A和/或5-HT1B受体中的其中一个或两者的拮抗剂。本发明的化合物在治疗或预防抑郁症、焦虑症、强迫症(OCD)和其他需要5-HT1激动剂或拮抗剂的疾病中具有用途,并且具有降低心脏副作用的潜力,特别是QTc延长。
  • Novel benayl(idene)-lactam derivatives
    申请人:Brodney A. Michael
    公开号:US20050245521A1
    公开(公告)日:2005-11-03
    The present invention relates to novel benzyl(idene)-lactam derivatives, compounds of the formula I wherein R 1 is a group of the formula G 1 or G 2 depicted below, wherein R 1 , R 3 , R 6 , R 13 X, a, n and m are as defined herein, their pharmaceutically acceptable salts, and pharmaceutical compositions which include selective antagonists, inverse agonists and partial agonists of serotonin 1 (5-HT 1 ) receptors, specifically, of one or both of the 5-HT 1A and 5-HT 1B receptors. The compounds of the invention are useful in treating or preventing depression, anxiety, obsessive compulsive disorder (OCD) and other disorders for which a 5-HT 1 agonist or antagonist is indicated and have reduced potential for cardiac side effects, in particular QTc prolongation.
    本发明涉及一种新型苯甲基(亚)内酰胺衍生物,化合物的式子为I,其中R1是下面所示的式子G1或G2的基团,其中R1、R3、R6、R13、X、a、n和m的定义如本说明书所述,其药学上可接受的盐,以及包括选择性5-羟色胺1(5-HT1)受体的拮抗剂、反向激动剂和部分激动剂的药物组合物,具体来说,是5-HT1A和5-HT1B受体中的一个或两个。本发明的化合物在治疗或预防抑郁症、焦虑症、强迫症和其他需要5-HT1受体激动剂或拮抗剂的疾病方面有用,并且具有减少心脏副作用的潜力,特别是QTc延长。
  • Design, synthesis and anticancer activity of functionalized spiro-quinolines with barbituric and thiobarbituric acids
    作者:Ravi Kiran Bhaskarachar、Vijayakumar G. Revanasiddappa、Subramanya Hegde、Janardhana P. Balakrishna、Suman Y. Reddy
    DOI:10.1007/s00044-015-1408-7
    日期:2015.9
    A new series of spiro-quinoline compounds have been accomplished by the reaction of barbituric acid or thiobarbituric acid with derivatives of benzisoxazole-5-carbaldehyde or 2-substituted benzaldehyde. These compounds were evaluated for their in vitro cytotoxicity on two mammalian cancer cell lines MCF-7 and KB. The compounds exhibit cytotoxicity against these cell lines in micromolar range. Among the series of compounds, 11(a-j) particularly 11b and 11e showed relatively good activity against both the tested cell lines. Compound 11b was found to exhibit the highest cytotoxic activity with IC50 value 90.2 mu M for MCF-7 and 49.8 mu M for KB cell line. Flow cytometric analysis study confirmed that these molecules induced cytotoxicity via apoptosis.
  • NOVEL BENZYL(IDENE)-LACTAM DERIVATIVES
    申请人:Pfizer Products Incorporated
    公开号:EP1727794A1
    公开(公告)日:2006-12-06
  • PROCEDE DE COLORATION UTILISANT UN PRECURSEUR DE COLORATION CAPILLAIRE ISSU D'IRIDOIDE, COMPOSITION, PRECURSEUR ET DISPOSITIF LE COMPRENANT
    申请人:L'OREAL
    公开号:EP2978767B1
    公开(公告)日:2018-10-03
查看更多